Why Are Karyopharm Shares Plunging Today? - Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc KPTI revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."
While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team:
- Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy.
- From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfolio management.
Karyopharm unveiled Phase 3 results for Xpovio in endometrial cancer, noting the drug cut the risk of disease progression or death by 30% compared to placebo, with median progression-free survival coming in at 5.7 months for the active arm and 3.8 months for the placebo cohort.
Price Action: KPTI shares are down 26.80% at $10.52 during the market session on the last check Tuesday.